Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer

Lung Cancer

Volumn 62, Issue 3, 2008, Pages 344-350

  Fruh M ^a   Gillessen, S ^a   Cerny, T ^a   Demmer, R ^a   D'Addario, G ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

First line; Fixed dose rate; Gemcitabine; NSCLC; Oxaliplatin; Phase II

Indexed keywords

GEMCITABINE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SKIN ABSCESS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 56949092503     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.028     Document Type: Article

References (32)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 8-29
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Crook J., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 19 (2001) 3210-3218
5. Monnet I., Brienza S., Hugret F., Voisin S., Gastiaburu J., Saltiel J.C., et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 34 (1998) 1124-1127
6. Raymond E., Faivre S., Woynarowski J.M., and Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 (1998) 4-12
7. Extra J.M., Marty M., Brienza S., and Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 (1998) 13-22
8. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., et al. A Phase 1 clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
9. Veerman G., Ruiz van Haperen V., Vermorken J.B., Noordhuis P., Braakhuis B.J., et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmocol 38 (1996) 335-342
10. Soo R.A., Wang L.Z., Tham L.S., Yong W.P., Boyer M., Lim H.L., et al. A multicentre randomised Phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17 (2006) 1128-1133
11. Tempero M., Plunkett W., Ruiz van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
12. Ceribelli A., Gridelli C., De Marinis F., Fabi A., Gamucci T., Cortesi E., et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized Phase II study of two different schedules in combination with cisplatin. Cancer 98 (2003) 337-343
13. Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G.V., Barbierei F., et al. A randomized Phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52 (2006) 319-325
14. Faivre S., Raymond E., Woynarowski J.M., and Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44 (1999) 117-123
15. Faivre S., Le Chevalier T., Monnerat C., Lokiec F., Novello S., Taieb J., et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13 (2002) 1479-1489
16. Bidoli P., Zilembo N., Cortinovis D., Mariani L., Isa L., Aitini E., et al. Randomized Phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer An Italian Trials in Medical Oncology study. Ann Oncol 18 (2007) 461-467
17. Franciosi V., Barbieri R., Aitini E., Vasini G., Cacciani G.C., Capra R., et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 41 (2003) 101-106
18. Kakolyris S., Ziras N., Vamvakas L., Varthalitis J., Papakotoulas P., Syrigos K., et al. Gemcitabine plus oxaliplatin combination (GEMOXregimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter Phase II study. Lung Cancer 54 (2006) 347-352
19. Hollen P.J., Gralla R.J., Kris M.G., and Potanovich L.M. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29 (1993) 51-58
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92 (2000) 205-216
21. Cox D.R., and Oakes D. Analysis of survival data (1984), Chapman & Hall, London
22. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), John Wiley & Sons Inc., New York
23. Fukuda M., Ohe Y., Kanzawa F., Oka M., Hara K., Saijo N., et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 15 (1995) 393-398
24. Mavroudis D., Pappas P., Kouroussis C., Kakorylis S., Agelaki S., Androulakis N., et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 14 (2003) 304-312
25. Shibata S., Chow W., Frankel P., Jushasz A., Leong L., Ling D., et al. A Phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemother Pharmacol 59 (2007) 549-557
26. Fosella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
27. Pereira J.R., Fein L., Del Giolio A., Blajman C.R., Richardet E., Schwartsmann G., et al. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 58 (2007) 80-87
28. Xu N., Shen P., Zhang X.C., Yu L.F., Bao H.Y., Shi G.M., et al. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59 (2007) 1-7
29. Gamelin E., Gamelin L., Bossi L., and Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 (2002) 21-33
30. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J Clin Oncol 22 (2005) 3509-3516
31. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
32. De Gramont A., Figer A., Seymour M., Homerin M., Hmissi M., Cassidy A., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947